US National Institutes of Health Intramural Research Program, Sanaria.

A double blind, randomized, controlled Phase 2 clinical trial was conducted to assess the safety, immunogenicity, and biologic impact of the vaccine candidate Apical Membrane Antigen 1-Combination 1 (AMA1-C1), adjuvanted with Alhydrogel ® . Participants were healthy children 2-3 years old living in or near the village of Bancoumana, Mali. A total of 300 children received either the study vaccine or the comparator. No impact of vaccination was seen on the primary endpoint, the frequency of parasitemia measured as episodes >3000 per μL per day at risk. There was a negative impact of vaccination on the hemoglobin level during clinical malaria, and mean incidence of hemoglobin <8.5 g/dL, in the direction of lower hemoglobin in the children who received AMA1-C1, although these differences were not significant after correction for multiple tests. These differences were not seen in the second year of transmission.

Division of Intramural Research, National Institute of Allergy and Infectious Diseases.

No abstract

A double blind, randomized, controlled Phase 1 clinical trial was conducted to assess the safety and immunogenicity in malaria exposed adults of the Plasmodium falciparum blood stage vaccine candidate Apical Membrane Antigen 1- Combination 1 (AMA1-C1)/Alhydrogel® with and without the novel adjuvant CPG 7909. Participants were healthy adults 18–45 years old living in the village of Donéguébougou, Mali. A total of 24 participants received 2 doses one month apart of either 80 μg AMA1-C1/Alhydrogel or 80 μg AMA1-C1/Alhydrogel + 564 μg CPG 7909. The study started in October 2007 and completed follow up in May 2008. Both vaccines were well tolerated, with only mild local adverse events and no systemic adverse events judged related to vaccination. The difference in antibody responses were over 2 fold higher in the group receiving CPG 7909 for all time points after second vaccination and the differences are statistically significant (all p<0.05). This is the first use of the novel adjuvant CPG 7909 in a malaria exposed population.